Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pucotenlimab plus short-course chemoradiotherapy as neoadjuvant therapy for MSS locally advanced rectal cancer
ChiCTR2500114938Phase 2Not yet recruiting
- Sponsor
- Fujian Provincial Hospital
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of pucotenlimab in rectal adenocarcinoma (2 arms), sponsored by Fujian Provincial Hospital. Primary endpoint: Complete Response (CR) Rate (pCR or sustained cCR). Planned start Dec 2025; status: not yet recruiting.
02
Drugs
pucotenlimab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500114938.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114938.